NCT04916574View on ClinicalTrials.gov

Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 20, 2021

Primary Completion Date

March 28, 2021

Study Completion Date

June 3, 2021

Conditions
SARS-COV2 InfectionCovid19
Interventions
OTHER

Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived from Bovine Colostrum

Concentration of active substance on nasal mucosal surface in time

Trial Locations (1)

61713

Icosagen AS, Tartu

All Listed Sponsors
collaborator

Tartu University Hospital

OTHER

lead

Icosagen Cell Factory

INDUSTRY

NCT04916574 - Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum | Biotech Hunter | Biotech Hunter